Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company based in Durham, N.C., is dedicated to developing and commercializing innovative therapeutic products for unmet patient needs. The company announced that its CEO, Scott Plesha, will be presenting at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 10:00 a.m. Eastern Time. This event will provide a platform for Pelthos to showcase its advancements and engage with investors, with management also scheduling one-on-one meetings for attendees interested in deeper discussions.

Pelthos Therapeutics is recognized for its focus on cutaneous infectious diseases, and its flagship product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, is the first prescription therapy approved for home use, enabling patients, parents, and caregivers to treat Molluscum contagiosum effectively. Other notable products in Pelthos' portfolio include Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice.

The company's commitment to addressing significant healthcare needs through its differentiated products positions it strategically within the biopharmaceutical sector. Interested investors can access a live webcast of Mr. Plesha’s presentation via the provided link and will also have the opportunity to view a replay on Pelthos' website for 90 days post-event. For more information about the company and its offerings, Pelthos encourages visits to its official website and their LinkedIn and X profiles.

For investor inquiries, LifeSci Advisors, LLC, led by Managing Director Mike Moyer, is available for contact, while media inquiries can be directed to KWM Communications.

Pelthos Therapeutics Inc. (NYSE American: PTHS) is poised for significant attention during the Oppenheimer 36th Annual Healthcare Life Sciences Conference, scheduled for February 26, 2026. The presentation by CEO Scott Plesha, alongside one-on-one investor meetings, offers a strategic opportunity for stakeholders to gain deeper insights into the company’s future prospects.

Pelthos focuses on innovative therapeutic solutions for unmet patient needs, with its lead product, ZELSUVMI™ (berdazimer) topical gel, currently the first and only FDA-approved prescription treatment for Molluscum contagiosum that can be applied at home. This unique offering positions Pelthos as a leader in addressing a common yet often overlooked skin condition, potentially capturing a significant share of the market for at-home treatment options.

Alongside ZELSUVMI™, the portfolio includes Xepi® for impetigo and Xeglyze® for head lice, demonstrating a comprehensive approach to cutaneous infectious diseases. This diversification not only mitigates risk but also allows for brand recognition within multiple patient demographics.

Investors should consider the upcoming presentation as critical for understanding Pelthos's growth trajectory, especially in light of its commercial-stage status. Key takeaways from this event may include updates on market performance, sales metrics, and future product developments which could greatly influence stock performance and investor sentiment.

The increasing demand for at-home treatment options and the company's strategic positioning within a growing niche market present a favorable outlook for Pelthos. Given its pipeline and market potential, investors may find PTHS attractive for medium- to long-term investment strategies, particularly if insights from the conference indicate robust future catalysts. It's advisable to monitor the reception of the presentation closely, as this may lead to volatility in stock price, providing potential entry points for investors.